Ethics and regulatory considerations for the clinical translation of somatic cell human epigenetic editing
Nikolajs Zeps, Tamra Lysaght, Ruth Chadwick, Alexandre Erler, Roger Foo, Simona Giordano, Poh San Lai, G. Owen Schaefer, Vicki Xafis, Wei Leong Chew, Jeremy Sugarman
Abstract
Altering the human epigenome with gene-editing technology in attempt to treat a variety of diseases and conditions seems scientifically feasible. We explore some of the ethical and regulatory issues related to the clinical translation of human epigenetic editing arguing that such approaches should be considered akin to somatic therapies. Altering the human epigenome with gene-editing technology in attempt to treat a variety of diseases and conditions seems scientifically feasible. We explore some of the ethical and regulatory issues related to the clinical translation of human epigenetic editing arguing that such approaches should be considered akin to somatic therapies.